A future of long-term, minimally toxic immunotherapy personalized to the cellular level is on the horizon—but only if manufacturers have the means to produce these therapies within a GMP environment.

Many increasingly used applications, such as cell line engineering and sequencing (including ATAC-seq and RNA-seq) along with single-cell genomics, require single-cell isolation as a starting point.

Single-cell cloning involves generating a cell line from a single initial cell isolated from a heterogeneous population, typically obtained through transfections, transductions, or primary cells ...